Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients - Archive ouverte HAL Access content directly
Journal Articles Blood Advances Year : 2021

Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients

(1, 2, 3) , (1, 2, 3) , (1, 4) , (1, 4) , (1, 4) , (1, 2, 3) , (1, 2, 3)
1
2
3
4

Abstract

Abstract It is essential to limit hemolytic transfusion reactions in polytransfused individuals, and the prevention of alloimmunization is a key solution. CD4+ T lymphocyte (TL) markers, particularly follicular T helper (Tfh) cells, may differentiate between responder and nonresponder alloimmunization statuses. We tested this hypothesis by studying the phenotype of CXCR5+PD1+ TLs in whole blood. Our results suggest that high levels of CXCR5+PD1+CD4+ TLs in whole blood may be a characteristic of nonalloimmunized patients. However, these cells did not display the phenotypic characteristics of active Tfh cells. Instead, a decrease in blood quiescent Tfh-cell levels was observed in nonalloimmunized polytransfused patients. High levels of CXCR5+PD1+CD4+ TLs may be associated with inhibitory signaling functions of T cells, as reflected by the low levels of PD1+ICOS+ cells in the nonalloimmunized polytransfused group. The description of these particular phenotypes, and their comparison among groups of patients, responders, and nonresponders, suggests that new immunological components should be considered when trying to understand posttransfusion alloimmunization.

Dates and versions

inserm-03218730 , version 1 (05-05-2021)

Identifiers

Cite

Marie Tamagne, Sadaf Pakdaman, Pablo Bartolucci, Anoosha Habibi, Frédéric Galactéros, et al.. Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients. Blood Advances, 2021, 5 (5), pp.1278-1282. ⟨10.1182/bloodadvances.2020003537⟩. ⟨inserm-03218730⟩

Collections

INSERM IMRB UPEC
10 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More